Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Research article

Comparative activity of carbapenem testing (the COMPACT study) in Turkey

Hakan Leblebicioglu1*, Nedim Cakir2, Mustafa Celen3, Halil Kurt4, Hakan Baris5, Joerg Laeuffer6 and Turkish COMPACT Study Group

Author Affiliations

1 Ondokuzmayis University, Kurupelit Kampüsü, PK 55139, Kurupelit, Samsun, Turkey

2 Dokuz Eylül University Infectious Disease Clinic, 35340, İnciralti İZMİR, Izmir, Turkey

3 Dicle University Infectious Disease Clinic, 21280, Diyarbakir, Turkey

4 Ankara University Infectious Disease Clinic, PK 06230, Altindağ, Gündoğdu Ankara, Turkey

5 Janssen-Turkey, Ertürk Sok, Keçeli Plaza No: 13 34810, Kavacik, Beykoz, Istanbul, Turkey

6 Janssen-EMEA, Sihlbruggstrasse 111, 6340, Baar, Switzerland

For all author emails, please log on.

BMC Infectious Diseases 2012, 12:42  doi:10.1186/1471-2334-12-42

Published: 16 February 2012

Abstract

Background

Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.

Methods

Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.

Results

Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.

Conclusions

Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.